Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture

Prostate

Volumn 43, Issue 1, 2000, Pages 31-42

  El Etreby, M Fathy ^a   Liang, Yayun ^a   Lewis, Ronald W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antiestrogens; Antiprogestins; bcl2; Cell growth inhibition; TGF 1

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; DNA FRAGMENT; MIFEPRISTONE; PROTEIN BCL 2; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL VIABILITY; COMPETITIVE INHIBITION; CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 0034030096     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(20000401)43:1<31::aid-pros5>3.0.co;2-%23     Document Type: Article

References (45)

1. Ekman P, Snochowski M, Dahlberg E, Gustafsson JA. Steroid receptors in metastatic carcinoma of the human prostate. Eur J Cancer 1979;15:257-262.
2. Robel P, Eychenne B, Blondeau JP, Baulieu EE, Hechter O. Sex steroid receptors in normal and hyperplastic prostate. Prostate 1985;6:255-267.
3. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992;20:281-295.
4. Ehara H, Koji T, Deguchi T, Yoshii A, Nakano M, Nakane PK, Kawada Y. Expression of estrogen receptor in diseased human prostate assessed by nonradioactive in situ hybridization and immunohistochemistry. Prostate 1995;27:304-313.
5. Mobbs BG, Johnson IE. Suppression of the growth of the androgen-insensitive R3327 HI rat prostatic carcinoma by combined estrogen and antiprogestin treatment. J Steroid Biochem Mol Biol 1991;39:713-722.
6. Parczky K, Schneider MR. The future of antihormone therapy: innovations based on an established principle-review. J Cancer Res Clin Oncol 1996;122:283-396.
7. Schnieder MR, Michna H, Nishino Y, El Etreby MF. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT-mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat. Eur J Cancer Clin Oncol 1989;25:691-701.
8. Michna H, Schneider MR, Nishino Y, El Etreby MF. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors; mechanistic studies. Breast Cancer Res Treat 1989;14:275-288.
9. Michna H, Schneider MR, Nishino Y, El Etreby MF. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem Mol Biol 1989;34:447-453.
10. Schneider MR, Michna H, Nishino Y, El Etreby MF. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 1990;37:783-787.
11. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998; 51:149-168.
12. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998;49:109-117.
13. Lin M-F, Kawachi MH, Stallcup MR, Grunberg SM, Lin F-F. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 1995;26:194-204.
14. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of antiestrogens. Breast Cancer Res Treat 1994;31:5-9.
15. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol 1995;50:723-726.
16. Astruc ME, Chabret C, Bali P, Gagne D, Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 1995;136:824-832.
17. Gundimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996;271:13504-13514.
18. Kiss Z, Anderson WH. Inhibition of phorbol ester-stimulated phospholipase D activity by chronic tamoxifen treatment in breast cancer cells. FEBS Lett 1997;400:145-148.
19. Cabot MC, Zhang Z, Cao H, Lavie Y, Giuliano AE, Han TY, Jones RC. Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int J Cancer 1997;70: 567-574.
20. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993;150:1544-1547.
21. Schneider MR, Schiller CD, Humm A, von Angerer E. Effect of zindoxifene on experimental prostatic tumors of the rat. J Cancer Res 1991;117:33-36.
22. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, Roberts AB, Sporn MB. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue RO 24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995;55:5621-5627.
23. Pienta KJ, Replogle T, Lehr JE. Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 1995;26:270-274.
24. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, Rooij HC, Trapman J, Brinkman AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990;173:534-540.
25. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LWK. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-412.
26. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54:2577-2581.
27. Rubenstein LV, Shoemaker RH, Paul KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-1118.
28. Hannan CJ, Liang Y, Allison JD, Searle JR. In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. Anticancer Res 1994;14:1517-1520.
29. 1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996;137:991-999.
30. 2 and bax but not p53 or Fas are involved in prostate cancer cell apoptosis induced by phenylbutyrate. In: Proceedings of the 89th Annual Meeting of the American Association for Cancer Research in New Orleans, LA, March 28-April 1, 1998, abstract #3882.
31. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
32. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
33. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-l expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
34. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995;55:735-738.
35. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
36. Bubendorf L, Sauter G, Moch H, Jordon P, Blochlinger A, Gasser TC, Mihtsch MJ. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;48:1557-1565.
37. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-5599.
38. Furuya Y, Isaacs JT. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 1994;25:301-309.
39. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration induced programmed cell death. Mol Endocrinol 1989;3:1515-1522.
40. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Different effects of transforming growth factor β on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989;62:79-87.
41. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim C-S, Fine RL, Robertson CN. Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC3 prostate cancer cells. Cell Growth Differ 1997;8:101-111.
42. 1 in nontumorigenic and tumorigenic rat prostate epithelial cell lines. Cancer Res 1996;56:5146-5149.
43. 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-1490.
44. Roberts AB, Spron MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Keine UI, Liotta LA, Flanaga V, Kehrl JH, Fauci AS. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
45. Welch DR, Farba A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990:87:7678-7682.